Having established that BRCA1 and BRCA2 expression was correlated with that of other HR genes in ovarian cancers, we sought to develop a targeted and less costly approach to measure BRCA1/2 mRNA levels in FFPE clinical samples. This evidence concerns the gene BRCA2 and ovarian cancer.